Host genetic factors and mycobacterial infections: lessons from single gene disorders affecting innate and adaptive immunity

Microbes and Infection

Volumn 8, Issue 4, 2006, Pages 1141-1150

  Doffinger, Rainer ^a   Patel, Smita Y ^a,b   Kumararatne, Dinakantha S ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Mycobacteria; Primary immunodeficiency

Indexed keywords

ADALIMUMAB; ADELUMIMAB; CD4 ANTIGEN; CORTICOSTEROID; ETANERCEPT; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; CELL FUNCTION; CELLULAR IMMUNITY; COMBINED IMMUNODEFICIENCY; COMPLEMENT SYSTEM; CROHN DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; GENE MUTATION; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; HYPERIMMUNOGLOBULINEMIA M; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFECTION SENSITIVITY; INNATE IMMUNITY; MACROPHAGE; MYCOBACTERIOSIS; MYCOSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SALMONELLOSIS; SEPSIS; SHORT SURVEY; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TUBERCULOSIS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; INTERFERON TYPE II; MACROPHAGES; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS;

CORYNEBACTERINEAE;

EID: 33646480768     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2005.10.028     Document Type: Short Survey

References (122)

1. Fischer A. Primary immunodeficiency diseases: an experimental model for molecular medicine. Lancet 357 9271 (2001) 1863-1869
2. Stephan J.L., et al. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J. Pediatr. 123 4 (1993) 564-572
3. Abramowsky C., Gonzalez B., and Sorensen R.U. Disseminated bacillus Calmette-Guerin infections in patients with primary immunodeficiencies. Am. J. Clin. Pathol. 100 1 (1993) 52-56
4. Romanus V., et al. Adverse reactions in healthy and immunocompromised children under six years of age vaccinated with the Danish BCG vaccine, strain Copenhagen 1331: implications for the vaccination policy in Sweden. Acta Paediatr. 82 12 (1993) 1043-1052
5. Minegishi M., et al. Successful transplantation of soy bean agglutinin-fractionated, histoincompatible, maternal marrow in a patient with severe combined immunodeficiency and BCG infection. Eur. J. Pediatr. 143 4 (1985) 291-294
6. Fisch P., et al. Expansion of gammadelta T cells in an infant with severe combined immunodeficiency syndrome after disseminated BCG infection and bone marrow transplantation. J. Allergy Clin. Immun. 103 6 (1999) 1218-1219
7. Heyderman R.S., et al. Successful bone marrow transplantation and treatment of BCG infection in two patients with severe combined immunodeficiency. Eur. J. Pediatr. 150 7 (1991) 477-480
8. Hugosson C., and Harfi H. Disseminated BCG-osteomyelitis in congenital immunodeficiency. Pediatr. Radiol. 21 5 (1991) 384-385
9. Culic S., et al. Disseminated BCG infection resembling langerhans cell histiocytosis in an infant with severe combined immunodeficiency: a case report. Pediatr. Hemat. Oncol. 21 6 (2004) 563-572
10. Fitoz S., et al. Bacillus Calmette-Guerin osteomyelitis in a patient with severe combined immunodeficiency: radiologic appearances of extensive dissemination. Curr. Probl. Diagn. Radiol. 33 1 (2004) 25-27
11. Han T.I., et al. Disseminated BCG infection in a patient with severe combined immunodeficiency. Korean J. Radiol. 1 2 (2000) 114-117
12. Hung G.Y., et al. Transplantation of related histocompatible marrow and peripheral blood stem cells in a patient with severe combined immunodeficiency and disseminated BCG infection. J. Chin. Med. Assoc. 66 1 (2003) 72-75
13. Ikinciogullari A., et al. An intensive approach to the treatment of disseminated BCG infection in a SCID patient. Bone Marrow Transpl. 30 1 (2002) 45-47
14. McKenzie R.H., and Roux P. Disseminated BCG infection following bone marrow transplantation for X-linked severe combined immunodeficiency. Pediatr. Dermatol. 17 3 (2000) 208-212
15. Skinner R., et al. Disseminated BCG infection in severe combined immunodeficiency presenting with severe anaemia and associated with gross hypersplenism after bone marrow transplantation. Bone Marrow Transpl. 17 5 (1996) 877-880
16. Uysal G., Guven M.A., and Sanal O. Subcutaneous nodules as presenting sign of disseminated BCG infection in a SCID patient. Infection 27 4-5 (1999) 293-294
17. Grumach A.S., et al. Brazilian report on primary immunodeficiencies in children: 166 cases studied over a follow-up time of 15 years. J. Clin. Immunol. 17 4 (1997) 340-345
18. Antaya R.J., et al. Cutaneous complications of BCG vaccination in infants with immune disorders: two cases and a review of the literature. Pediatr. Dermatol. 18 3 (2001) 205-209
19. Jung E.Y., et al. X-linked severe combined immunodeficiency with gamma delta T cells. Acta. Paediatr. Japon 39 4 (1997) 442-447
20. Kohn T., et al. [Histomorphology of BCG infections in patients with severe combined immunodeficiency]. Verh. Dtsch. Ges. Pathol. 75 (1991) 195-199
21. Gonzalez B., et al. Clinical presentation of Bacillus Calmette-Guerin infections in patients with immunodeficiency syndromes. Pediatr. Infect. Dis. J. 8 4 (1989) 201-206
22. Parent L.J., et al. Disseminated Mycobacterium marinum infection and bacteremia in a child with severe combined immunodeficiency. Clin. Infect. Dis. 21 5 (1995) 1325-1327
23. Kiehn T.E., et al. Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics. J. Clin. Microbiol. 21 2 (1985) 168-173
24. Deerojanawong J., et al. Pulmonary diseases in children with severe combined immune deficiency and DiGeorge syndrome. Pediatr. Pulm. 24 5 (1997) 324-330
25. Lopez-Herrera G., et al. Severe combined immunodeficiency syndrome associated with colonic stenosis. Arch. Med. Res. 35 4 (2004) 348-358
26. Nagasawa M., et al. Pulmonary miliary tuberculosis and T-cell abnormalities in a severe combined immunodeficient patient reconstituted with haploidentical bone marrow transplantation. Int. J. Hematol. 59 4 (1994) 303-309
27. Durandy A., Revy P., and Fischer A. Human models of inherited immunoglobulin class switch recombination and somatic hypermutation defects (hyper-IgM syndromes). Adv. Immunol. 82 (2004) 295-330
28. Ferrari S., and Plebani A. Cross-talk between CD40 and CD40L: lessons from primary immune deficiencies. Curr. Opin. Allergy Cl. 2 6 (2002) 489-494
29. Levy J., et al. Clinical spectrum of X-linked hyper-IgM syndrome. J. Pediatr. 131 1 Pt 1 (1997) 47-54
30. Winkelstein J.A., et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 82 6 (2003) 373-384
31. Lazarevic V., et al. CD40, but not CD40L, is required for the optimal priming of T cells and control of aerosol M. tuberculosis infection. Immunity 19 6 (2003) 823-835
32. Etzioni A., et al. The hyper IgM syndrome - an evolving story. Human models of inherited immunoglobulin class switch recombination and somatic hypermutation defects (hyper-IgM syndromes). Pediatr. Res. 56 4 (2004) 519-525
33. Grimbacher B., Holland S.M., and Puck J.M. Hyper-IgE syndromes. Immunol. Rev. 203 (2005) 244-250
34. Pasic S. Local bacillus Calmette-Guerin infection in hyperimmunoglobulin-E syndrome. Acta. Paediatr. 91 11 (2002) 1271-1272
35. Pasic S., et al. Disseminated Bacillus Calmette-Guerin infection in a girl with hyperimmunoglobulin E syndrome. Acta. Paediatr. 87 6 (1998) 702-704
36. Metin A., et al. Tuberculous brain abscess in a patient with hyper IgE syndrome. Pediatr. Int. 46 1 (2004) 97-100
37. Gotzberger M., et al. A rare cause of gastrointestinal bleeding in a patient with hyper-IgE syndrome. Gut 53 10 (2004) 1430-1436
38. Ito R., et al. Selective insufficiency of IFN-gamma secretion in patients with hyper-IgE syndrome. Allergy 58 4 (2003) 329-336
39. Borges W.G., Augustine N.H., and Hill H.R. Defective interleukin-12/interferon-gamma pathway in patients with hyperimmunoglobulinemia E syndrome. J. Pediatr. 136 2 (2000) 176-180
40. Del Prete G., Ricci M., and Romagnani S. T cells, IgE antibodies, cytokines and allergic inflammation. Allergy Immunol. (Paris) 23 6 (1991) 239-243
41. Abinun M., et al. Anhidrotic ectodermal dysplasia associated with specific antibody deficiency. Eur. J. Pediatr. 155 2 (1996) 146-147
42. Puel A., et al. Inherited disorders of NF-kappaB-mediated immunity in man. Curr. Opin. Immunol. 16 1 (2004) 34-41
43. Zonana J., et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am. J. Hum. Genet. 67 6 (2000) 1555-1562
44. Döffinger R., et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat. Genet. 27 3 (2001) 277-285
45. Jain A., et al. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat. Immunol. 2 3 (2001) 223-228
46. Aradhya S., et al. Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-gamma). Am. J. Hum. Genet. 68 3 (2001) 765-771
47. Smahi A., et al. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 405 6785 (2000) 466-472
48. Dai Y.S., et al. Characteristics of mycobacterial infection in patients with immunodeficiency and nuclear factor-kappaB essential modulator mutation, with or without ectodermal dysplasia. J. Am. Acad. Dermatol. 51 5 (2004) 718-722
49. Niehues T., et al. Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J. Allergy Clin. Immun. 114 6 (2004) 1456-1462
50. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl. (2002) S81-S96
51. Verma I.M. Nuclear factor (NF)-kappaB proteins: therapeutic targets. Ann. Rheum. Dis. 63 Suppl. 2 (2004) ii57-ii61
52. Dupuis-Girod S., et al. Osteopetrosis, lymphedema, anhidrotic ectodermal dysplasia, and immunodeficiency in a boy and incontinentia pigmenti in his mother. Pediatrics 109 6 (2002) e97
53. Orange J.S., et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J. Clin. Invest. 109 11 (2002) 1501-1509
54. Mansour S., et al. Incontinentia pigmenti in a surviving male is accompanied by hypohidrotic ectodermal dysplasia and recurrent infection. Am. J. Med. Genet. 99 2 (2001) 172-177
55. Orange J.S., et al. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J. Allergy Clin. Immun. 113 4 (2004) 725-733
56. Picard C., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299 5615 (2003) 2076-2079
57. Medvedev A.E., et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198 4 (2003) 521-531
58. Chapel H., et al. Shigella sonnei meningitis due to interleukin-1 receptor-associated kinase-4 deficiency: first association with a primary immune deficiency. Clin. Infect. Dis. 40 9 (2005) 1227-1231
59. Courtois G., et al. A hypermorphic I{kappa}B{alpha} mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J. Clin. Invest. 112 7 (2003) 1108-1115
60. Janssen R., et al. The same IkappaBalpha mutation in two related individuals leads to completely different clinical syndromes. J. Exp. Med. 200 5 (2004) 559-568
61. Casanova J.L., and Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20 (2002) 581-620
62. Feinberg J., et al. Bacillus Calmette Guerin triggers the IL-12/IFN-gamma axis by an IRAK-4- and NEMO-dependent, non-cognate interaction between monocytes, NK, and T lymphocytes. Eur. J. Immunol. (2004)
63. Casanova J.L., et al. Idiopathic disseminated bacillus Calmette-Guerin infection: a French national retrospective study. Pediatrics 98 4 Pt 1 (1996) 774-778
64. Casanova J.L., et al. Immunological conditions of children with BCG disseminated infection. Lancet 346 8974 (1995) 581
65. Frucht D.M., and Holland S.M. Defective monocyte costimulation for IFN-gamma production in familial disseminated Mycobacterium avium complex infection: abnormal IL-12 regulation. J. Immunol. 157 1 (1996) 411-416
66. Levin M., et al. Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene?. Lancet 345 8942 (1995) 79-83
67. McKusick V.A. Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. 12th ed. (1998), Johns Hopkins University Press., Baltimore
68. Frucht D.M., et al. IL-12-Independent costimulation pathways for interferon-gamma production in familial disseminated Mycobacterium avium complex infection. Clin. Immunol. 91 2 (1999) 234-241
69. Jouanguy E., et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat. Genet. 21 4 (1999) 370-378
70. Villella A., et al. Recurrent Mycobacterium avium osteomyelitis associated with a novel dominant interferon gamma receptor mutation. Pediatrics 107 4 (2001) E47 Public Health; and Baltimore City Health Department Eastern Chest Clinic, Baltimore, MD, U.S.A. tsterls@jhmi.edu.
71. Emile J.F., et al. Correlation of granuloma structure with clinical outcome defines two types of idiopathic disseminated BCG infection. J. Pathol. 181 1 (1997) 25-30
72. Jouanguy E., et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 335 26 (1996) 1956-1961
73. Newport M.J., et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335 26 (1996) 1941-1949
74. Dorman S.E., and Holland S.M. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J. Clin. Invest. 101 11 (1998) 2364-2369
75. Dupuis S., et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 293 5528 (2001) 300-303
76. Dupuis S., et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat. Genet. (2003)
77. de Jong R., et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280 5368 (1998) 1435-1438
78. Picard C., et al. Inherited Interleukin-12 Deficiency: IL12B Genotype and Clinical Phenotype of 13 Patients from Six Kindreds. Am. J. Hum. Genet. 70 2 (2002) 336-348
79. Dorman S.E., et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 364 9451 (2004) 2113-2121
80. Döffinger R., et al. Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guerin and Mycobacterium abscessus infection. J. Infect. Dis. 181 1 (2000) 379-384
81. MacLennan C., et al. Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans. J. Infect. Dis. 190 10 (2004) 1755-1757
82. Riordan J.R., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 4922 (1989) 1066-1073
83. Oliver A., et al. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin. Infect. Dis. 32 9 (2001) 1298-1303
84. Kilby J.M., et al. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 102 1 (1992) 70-75
85. Aitken M.L., et al. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest 103 4 (1993) 1096-1099
86. Torrens J.K., et al. Non-tuberculous mycobacteria in cystic fibrosis. Thorax 53 3 (1998) 182-185
87. Olivier K.N., et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am. J. Resp. Crit. Care 167 6 (2003) 835-840
88. Olivier K.N., et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am. J. Respir. Crit. Care 167 6 (2003) 828-834
89. Taggart C.C., et al. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J. Immunol. (2003) 931-937
90. Goldman M.J., et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88 (1997) 553-560
91. Bals R., Weiner D.J., and Wilson J.M. The innate immune system in cystic fibrosis lung disease. J. Clin. Invest. 103 3 (1999) 303-307
92. Jayaraman S., et al. Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na(+)] and pH but elevated viscosity. Proc. Natl. Acad. Sci. U.S.A. 98 14 (2001) 8119-8123
93. Lyczak J.B., and Pier G.B. Salmonella enterica serovar typhi modulates cell surface expression of its receptor, the cystic fibrosis transmembrane conductance regulator, on the intestinal epithelium. Infect. Immun. 70 11 (2002) 6416-6423
94. Schroeder T.H., et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc. Natl. Acad. Sci. U.S.A. 99 10 (2002) 6907-6912
95. Poschet J., Perkett E., and Deretic V. Hyperacidification in cystic fibrosis: links with lung disease and new prospects for treatment. Trends Mol. Med. 8 11 (2002) 512-519
96. Poschet J.F., et al. Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung. Proc. Natl. Acad. Sci. U.S.A. 98 24 (2001) 13972-13977
97. Poschet J.F., et al. Hyperacidification of cellubrevin endocytic compartments and defective endosomal recycling in cystic fibrosis respiratory epithelial cells. J. Biol. Chem. 277 16 (2002) 13959-13965
98. Gardam M.A., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect. Dis. 3 3 (2003) 148-155
99. Wallis R.S., et al. Reply to schaible. Clin. Infect. Dis. 39 8 (2004) 1256
100. Wallis R.S., et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis. 39 8 (2004) 1254-1255
101. Schaible T.F. Inconsistencies in reporting of granulomatous infectious diseases associated with infliximab and etanercept. Clin. Infect. Dis. 39 8 (2004) 1255-1256 author reply 1256
102. Hein R., et al. Granulomatous inflammation with combined immunodeficiency. Immun. Infekt. 18 2 (1990) 48-50
103. Ozsahin H., et al. Adenosine deaminase deficiency in adults. Blood 89 8 (1997) 2849-2855
104. Vergne I., et al. Cell biology of mycobacterium tuberculosis phagosome. Annu. Rev. Cell Dev. Biol. (2004) 367-394
105. Russell D.G. Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. Mol. Cell Biol. (2001) 569-577
106. Malik Z.A., Iyer S.S., and Kusner D.J. Mycobacterium tuberculosis phagosomes exhibit altered calmodulin-dependent signal transduction: contribution to inhibition of phagosome-lysosome fusion and intracellular survival in human macrophages. J. Immunol. (2001) 3392-3401
107. Malik Z.A., et al. Cutting edge: Mycobacterium tuberculosis blocks Ca2+ signaling and phagosome maturation in human macrophages via specific inhibition of sphingosine kinase. J. Immunol. (2003) 2811-2815
108. Vergne I., Chua J., and Deretic V. Tuberculosis toxin blocking phagosome maturation inhibits a novel Ca2+/calmodulin-PI3K hVPS34 cascade. J. Exp. Med. (2003) 653-659
109. Simonsen A., et al. EEA1 links PI(3)K function to Rab5 regulation of endosome fusion. Nature (1998) 494-498
110. Simonsen A., et al. The Rab5 effector EEA1 interacts directly with syntaxin-6. J. Biol. Chem. (1999) 28857-28860
111. Lemmon M.A. Phosphoinositide recognition domains. Traffic. (2003) 201-213
112. Vieira O.V., Botelho R.J., and Grinstein S. Phagosome maturation: aging gracefully. Biochem. J. (2002) 689-704
113. Fratti R.A., et al. Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. J. Cell Biol. (2001) 631-644
114. de Chastellier C., and Thilo L. Pathogenic Mycobacterium avium remodels the phagosome membrane in macrophages within days after infection. Eur. J. Cell Biol. 81 1 (2002) 17-25
115. Kusner D.J. Mechanisms of mycobacterial persistence in tuberculosis. Clin. Immunol. 114 3 (2005) 239-247
116. Pieters J., and Gatfield J. Hijacking the host: survival of pathogenic mycobacteria inside macrophages. Trends Microbiol. 10 3 (2002) 142-146
117. Vergne I., et al. Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. (2005) 4033-4038
118. Fratti R.A., Chua J., and Deretic V. Induction of p38 mitogen-activated protein kinase reduces early endosome autoantigen 1 (EEA1) recruitment to phagosomal membranes. J. Biol. Chem. (2003) 46961-46967
119. Anes E., et al. Selected lipids activate phagosome actin assembly and maturation resulting in killing of pathogenic mycobacteria. Nat. Cell Biol. (2003) 793-802
120. MacMicking J.D., Taylor G.A., and McKinney J.D. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science (2003) 654-659
121. MacMicking J.D. Immune control of phagosomal bacteria by p47 GTPases. Curr. Opin. Microbiol. (2005) 74-82
122. Gutierrez M.G., et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell (2004) 753-766